A case report of erlotinib-induced trichomegaly in a glaucoma patient

A case report of erlotinib-induced trichomegaly in a glaucoma patient

Author(s)

Aysha S Falamarzi, Mohammed Yusuf Shaikh

Abstract

Trichomegaly of the eyelashes is an uncommon side effect of erlotinib, which is an epidermal growth factor receptor kinase inhibitor. Erlotinib is a form of molecular targeted therapy, increasingly used in the treatment of wide variety of cancers.

The purpose of this case presentation is to highlight the occurrence of erlotinib-induced trichomegaly of eyelashes in a known patient of glaucoma on topical ocular hyoptensives other than prostaglandins.

 The report aims to highlight specifically the difficulties that trichomegaly poses in glaucoma management and reminds of other ophthalmic side effects of erlotinib.

The recognition of this sporadically reported uncommon condition and its management is essential not only to ensure acceptable cosmesis and ocular comfort but also to prevent serious ocular complication.

Al-Basar International Journal Of Ophthalmology

DOI: 10.4103/bijo.bijo_4_19

Available on: https://www.bijojournal.org/article.asp?issn=1858-6538;year=2019;volume=6;issue=1;spage=13;epage=15;aulast=Falamarzi